Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 4
1990 4
1991 17
1992 24
1993 23
1994 36
1995 26
1996 48
1997 42
1998 39
1999 33
2000 39
2001 40
2002 37
2003 45
2004 39
2005 45
2006 50
2007 34
2008 37
2009 41
2010 40
2011 35
2012 35
2013 47
2014 53
2015 45
2016 49
2017 63
2018 53
2019 55
2020 36
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

1,123 results
Results by year
Filters applied: . Clear all
Page 1
Epidermolysis bullosa: Advances in research and treatment.
Prodinger C, Reichelt J, Bauer JW, Laimer M. Prodinger C, et al. Exp Dermatol. 2019 Oct;28(10):1176-1189. doi: 10.1111/exd.13979. Epub 2019 Aug 8. Exp Dermatol. 2019. PMID: 31140655 Free PMC article. Review.
There is no cure for any of the subtypes of EB resulting from different mutations, and current therapy only focuses on the management of wounds and pain. Novel effective therapeutic approaches are therefore urgently required. Strategies include gene-, protein- and cell-bas …
There is no cure for any of the subtypes of EB resulting from different mutations, and current therapy only focuses on the management of wou …
The Evolution of Topical Formulations in Psoriasis.
Kuehl B, Shear NH. Kuehl B, et al. Skin Therapy Lett. 2018 Jul;23(4):5-9. Skin Therapy Lett. 2018. PMID: 30086183 Free article. Review.
However, adherence to topical treatment remains a challenge, as the daily application creates a significant treatment burden. New topical therapeutic options need to offer higher efficacy and better patient acceptability, including easier application, to reduce treatment b …
However, adherence to topical treatment remains a challenge, as the daily application creates a significant treatment burden. New topical …
Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL. McCormack PL. Am J Clin Dermatol. 2011 Dec 1;12(6):421-4. doi: 10.2165/11207670-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21967117 Review.
Calcipotriene (calcipotriol)/betamethasone dipropionate (calcipotriene 50 mug/g and betamethasone 0.5 mg/g) is a fixed-dose combination of a vitamin D3 analog and a corticosteroid indicated for the once-daily, topical treatment of psoriasis vulgaris of the tr
Calcipotriene (calcipotriol)/betamethasone dipropionate (calcipotriene 50 mug/g and betamethasone 0.5 mg/g) is a fixed-
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.
Rosenberg AR, Tabacchi M, Ngo KH, Wallendorf M, Rosman IS, Cornelius LA, Demehri S. Rosenberg AR, et al. JCI Insight. 2019 Mar 21;4(6):e125476. doi: 10.1172/jci.insight.125476. eCollection 2019 Mar 21. JCI Insight. 2019. PMID: 30895944 Free PMC article. Clinical Trial.
However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention is unknown. METHODS: We performed a blinded prospective cohort study on participants of a randomized double-blind clinical trial in which a 4-day course of topical calcipotriol
However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention is unknown. METHODS: We performed a blind …
Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review.
Yan R, Jiang S, Wu Y, Gao XH, Chen HD. Yan R, et al. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):135-44. doi: 10.4103/0378-6323.175919. Indian J Dermatol Venereol Leprol. 2016. PMID: 26924402 Free article. Review.
The methodologies of the studies were generally of moderate to high quality. These trials used topical calcipotriol/betamethasone dipropionate for 4 or 8 weeks, and were compared with topical calcipotriol or betamethasone. ...The adverse events of calcipotriol
The methodologies of the studies were generally of moderate to high quality. These trials used topical calcipotriol/betamethasone dip …
Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.
Frieder J, Kivelevitch D, Menter A. Frieder J, et al. Ther Deliv. 2017 Aug;8(9):737-746. doi: 10.4155/tde-2017-0058. Epub 2017 Jun 29. Ther Deliv. 2017. PMID: 28659016 Review.
Mainstay topical treatments include corticosteroids and vitamin D derivatives. Calcipotriene/betamethasone dipropionate aerosol foam is a novel single product combination, which seeks to provide superior therapeutic efficacy in addition to enhanced cosmetic properti …
Mainstay topical treatments include corticosteroids and vitamin D derivatives. Calcipotriene/betamethasone dipropionate aerosol foam …
Topical application of calcipotriene and corticosteroids: combination regimens.
Lebwohl M. Lebwohl M. J Am Acad Dermatol. 1997 Sep;37(3 Pt 2):S55-8. J Am Acad Dermatol. 1997. PMID: 9344186 Review.
BACKGROUND: Side effects of topical corticosteroids limit their long-term use. Calcipotriene/calcipotriol (Dovonex/Daivonex) ointment is not associated with any of the side effects of corticosteroids and has been shown to thicken the skin in contrast to the c …
BACKGROUND: Side effects of topical corticosteroids limit their long-term use. Calcipotriene/calcipotriol (Dovonex/Daiv …
Trends in on and off-label calcipotriene use.
Pearce DJ, Camacho F, Balkrishnan R, Fleischer AB Jr, Feldman SR. Pearce DJ, et al. J Dermatolog Treat. 2006;17(5):308-13. doi: 10.1080/09546630600813659. J Dermatolog Treat. 2006. PMID: 17092863
Nearly 57% of mentions of calcipotriene were not linked to a diagnosis of psoriasis. Adjusted use for gender and race were relatively stable; there was a rise in non-psoriasis uses and use among non-dermatologists in 1997. Our findings support previous report …
Nearly 57% of mentions of calcipotriene were not linked to a diagnosis of psoriasis. Adjusted use for gender and race were rel …
The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis.
Thiers BH. Thiers BH. J Am Acad Dermatol. 1997 Sep;37(3 Pt 2):S69-71. J Am Acad Dermatol. 1997. PMID: 9344189 Review.
BACKGROUND: Topical calcipotriene ointment has been approved for the treatment of plaque-type psoriasis. OBJECTIVE: This article explores the possible use of topical calcipotriene ointment in the treatment of nail and intertriginous psoriasis, palmoplantar an …
BACKGROUND: Topical calcipotriene ointment has been approved for the treatment of plaque-type psoriasis. OBJECTIVE: This article expl …
[Calcipotriol].
Guilhou JJ. Guilhou JJ. Ann Dermatol Venereol. 2001 Mar;128(3 Pt 1):229-37. Ann Dermatol Venereol. 2001. PMID: 11319386 Free article. Review. French.
Calcipotriol is a vitamin D derivative synthesized in 1985 by the Leo Laboratories. ...Therapeutic trials in psoriasis have demonstrated the superiority of Calcipotriol over its excipient, class 2 dermatocorticoids, and reducers. ...
Calcipotriol is a vitamin D derivative synthesized in 1985 by the Leo Laboratories. ...Therapeutic trials in psoriasis have de
1,123 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page